GlassScriptPhysician profile
Judith Ann Schaetzer
NPI 1043963689
$5,230.64
in general payments reported to CMS, 2019-2025
19 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2023: $1,601 · 2024: $1,593 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,072 · Education: $48.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.06 |
| Education | $48.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.24 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $608.84 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $579.38 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $551.96 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $499.31 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $461.22 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $310.07 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $308.14 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $280.39 | 2024-2025 | Cobenfy |
| Indivior INC. | $239.68 | 2022-2025 | Sublocade, Perseris |
| Supernus Pharmaceuticals, INC. | $168.55 | 2023-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $139.06 | 2023-2025 | Fanapt, Hetlioz |
| Corium, LLC | $124.40 | 2023-2024 | Azstarys |
| Braeburn INC. | $104.36 | 2023-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $43.08 | 2022-2023 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $39.78 | 2023-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $21.81 | 2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $19.79 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.58 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Schaetzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.